NDAORALTABLET
Approved
Jul 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PEXEVA (paroxetine mesylate) is an oral selective serotonin reuptake inhibitor (SSRI) approved in 2003 for treating depression and anxiety disorders. It works by increasing serotonin availability in the brain through reuptake inhibition. The mesylate salt formulation provides an alternative delivery mechanism for patients requiring paroxetine therapy.
$0.508MPart D
LOE ApproachingDeclining
Significantly contracted patient base and spend signal a mature branded product with limited growth opportunity and likely reduced team headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PEXEVA offers minimal career growth potential given its LOE-approaching lifecycle, minimal Part D spending ($508K annually), and declining patient claims (594 in 2023). Roles tied to this product are typically focused on managing decline, defending market share, and ensuring compliance rather than strategic expansion or innovation.
Brand ManagerMedical Science Liaison
Worked on PEXEVA at Bel Air Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.